search

menu

  • Research Research
    • Where science meets inspired minds

    • Back
    • Research
    • Our Science
    • Research Groups
    • Facilities & Platforms
    • Clinical research
    • Find a researcher
    • Publications
    • Knowledge Transfer
  • Careers & study Careers & study
    • Become a leader in cancer research

    • Back
    • Careers & study
    • Vacancies
    • Faculty
    • Scientific staff
    • Scientific support staff
    • Postdoctoral fellows
    • PhD Students
    • Operational staff
    • Clinical fellows
    • Life in Amsterdam
    • Student internships
  • News & Events News & Events
    • Check out our stories and events

    • Back
    • News & Events
    • News
    • Media & Press
    • Calendar
  • About us About us
    • Maximum impact for cancer patients

    • Back
    • About us
    • Our vision
    • Organization
    • Collaborations
    • Responsible Research
    • Support us
    • Visit us
    • Contact us
  • Support us
Support us
  • Home
  • Publications
  • Research
  • Publications
  • Article

Contrast-enhanced Mammography for Breast Cancer Screening in Women at Increased Risk: Comparison of Prevalence and Incidence Screens.

Carol H Lee ,
Tali Amir ,
Varadan Sevilimedu ,
Sarah Eskreis-Winkler ,
Delia Keating ,
Donna D'Alessio ,
Maxine S Jochelson ,
Gordon P Watt ,
Kimberly N Feigin ,
Noam Nissan ,
Hila Fruchtman-Brot ,
Christopher E Comstock ,
Janice S Sung

Abstract

Background Studies have reported the value of contrast-enhanced mammography (CEM) for screening women at increased risk for breast cancer, based on prevalence ("baseline") screening. Purpose To compare the performance of CEM between prevalence and incidence screens in women at increased risk for breast cancer. Materials and Methods This retrospective study included CEM screens from January 2015 through December 2021. Screens were categorized as prevalence if there was no prior breast MRI in the past 3 years or no prior CEM; all others were incidence screens. Performance metrics, including cancer detection rate (CDR), incremental CDR (cancers found through enhancement on recombined images with negative low-energy [26-30 kVp] images), sensitivity, specificity, positive predictive value, negative predictive value, and accuracy, were compared between prevalence and incidence screens. Reference standards for malignant and benign results were biopsy or negative imaging follow-up in 1 year. P values were estimated using a generalized estimating equation model. Results Of 6911 screens in 2756 women (median age, 52 years [IQR, 46-58 years]), 1575 (22.8%) were prevalence screens and 5336 (77.2%) were incidence screens. Adjusting for the number of screens per individual, there was no evidence of a difference in CDR between prevalence and incidence screens (19 cancers per 1000 prevalence screens vs 11.6 cancers per 1000 incidence screens; P = .65) or in incremental CDR (11.4 per 1000 prevalence screens vs 6.7 per 1000 incidence screens; P = .10). Incidence CEM had higher specificity than prevalence CEM (91.5% [95% CI: 90.7, 92.2] vs 83.4% [95% CI: 81.6, 85.4]; P = .008), and higher accuracy (91.4% [95% CI: 90.6, 92.2] vs 83.5% [95% CI: 81.7, 85.4]; P = .01). Contrast enhancement alone helped detect 18 of 30 (60%) cancers during prevalence screening and 36 of 62 (58%) during incidence screening. Conclusion CEM continues to help detect cancers during incidence screening with improved specificity compared with prevalence screens. © RSNA, 2026 Supplemental material is available for this article. See also the editorial by Freitas in this issue.

More about this publication

Radiology

Volume 320
Issue nr. 1
Pages e252433
Publication date 01-07-2026

Full text links

Publisher website (DOI) 10.1148/radiol.252433
Europe PubMed Central 42517765
Pubmed 42517765

Where science meets inspired minds

Contact

Plesmanlaan 121
1066CX Amsterdam

020 512 9111 communicatie@nki.nl

Quick links

  • Vacancies
  • News
  • Contact us
  • Media & Press

Follow us on

Disclaimer
Privacy statement
Cookies
Change cookie settings

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.